Premium
Ticlopidine‐induced aplastic anemia: Development of chromosomal abnormalities and response to immunosuppressive therapy
Author(s) -
Pullarkat Vinod A.,
Rho Hyan,
MurataCollins Joyce L.,
Liebman Howard A.
Publication year - 2000
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/(sici)1096-8652(200003)63:3<141::aid-ajh6>3.0.co;2-t
Subject(s) - medicine , aplastic anemia , immunosuppression , hypoplasia , gastroenterology , anemia , erythropoiesis , chemotherapy , bone marrow , immunology
Severe aplastic anemia is a well‐recognized complication of ticlopidine therapy that carries a high mortality. Therapy with colony‐stimulating factors or corticosteroids has been largely ineffective in this disorder. We report a case of ticlopidine‐induced aplastic anemia that was successfully treated with cyclosporine and high‐dose dexamethasone. The patient rapidly responded to immunosuppressive therapy and had a normal hemogram after cessation of immunosuppression. On long‐term follow‐up, the patient developed a progressive macrocytic anemia. Repeat bone marrow evaluation demonstrated myelodysplasia with erythroid hypoplasia. An associated chromosomal abnormality consisting of a t(3;16) (q21; p13.3) translocation was detected. This is the first report of a chromosomal abnormality associated with ticlopidine induced marrow aplastic anemia. Am. J. Hematol. 63:141–144, 2000. © 2000 Wiley‐Liss, Inc.